Reasonably good Q2, despite underlying challenges/risks
13/05/22 -"Despite the supply-chain challenges, CZM reported a reasonably good set of Q2 21/22 results. Both segments reported double-digit growth and order intake was impressive. Unlike most of the MedTech ..."
Pages
63
Language
English
Published on
13/05/22
You may also be interested by these reports :
19/11/26
Dräger’s CMD delivered more than expected: Ambition 2030 targets c.€4.5bn of sales and a 10–12% EBIT margin, above July’s “at least 10%”, backed for ...
17/11/26
Getinge delivered a mixed Q3 26, with sales marginally below consensus but adjusted EBITA well ahead. ACT drove a sharp margin step-up, even before ...
13/11/26
DiaSorin’s Q3 performance exceeded expectations, with revenue acceleration supported by all segments and improved profitability. Full-year guidance ...
13/11/26
Coloplast reported weak Q4 FY26 numbers: revenue beat consensus slightly (+1.1%), but adjusted EBIT missed sharply (-8.4%). More importantly, the new ...